Skip to content

Virtual Exercise for Multiple Myeloma

Feasibility of a Virtually Supported Home-Based Resistance and Aerobic Exercise Program for Cancer Survivors With Multiple Myeloma

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04484714
Acronym
MY-PROGRESS
Enrollment
31
Registered
2020-07-23
Start date
2020-09-15
Completion date
2021-08-31
Last updated
2021-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

exercise, pilot, feasibility

Brief summary

The primary objective of this pilot study is to determine the safety and feasibility a 12-week virtually supported home-based aerobic and resistance exercise program progressing cancer survivors with Multiple Myeloma to meet standards identified in the 2019 Exercise Guidelines for Cancer Survivors. The protocol will be measuring recruitment, adherence, completion, cost tracking, as well as fitness and quality of life outcomes. The study will be a single-group prospective before and after study that will help inform a future larger-scale project. We will aim to recruit 25 participants. The Health Research Ethics Board of Alberta Cancer Committee will approve this study. Participants will participate in a combined resistance and aerobic exercise program biweekly for 12 weeks. Exercise sessions will be supported and progressive in nature, between 40 and 75 minutes each. Analyses: fitness testing and quality of life scales will be administered before and after the intervention. Scores will be compared to evaluate changes over the course of the intervention. Safety and feasibility information will be collected throughout the study and evaluated to determine program feasibility. Program satisfaction will be evaluated using a satisfaction survey.

Detailed description

Multiple myeloma (MM), a cancer of the plasma cells in bone marrow, is associated with osteolytic bone destruction, leading to deformities, chronic pain, reduced mobility and functioning, fatigue, and risk of fracture. Although incurable, newly developed therapies are extending survival, but some with significant side-effects. Patients may be living longer but with lasting, debilitating side-effects. Exercise has been proposed as a way to optimize patient function and quality of life in the face of lasting symptom burden. However, current evidence-informed exercise guidelines for cancer survivors may not be appropriate for those with bone fragility, including those with MM, as they are based on findings from studies in breast and prostate cancers. In MM specifically, the literature presents mixed results, and several studies have limited generalizability, reproducibility, or were underdosed. The main objective of this study is to determine the safety and feasibility of a 12-week virtually supported home-based aerobic and resistance exercise program that aims to progress individuals to the 2019 Exercise Guidelines for Cancer Survivors in a sample of cancer survivors with multiple myeloma, as defined by: * Recruitment rate: ≥ 21 participants consenting to the study over a 7-month recruitment period (primary endpoint) * Completion rate: ≥ 80% of participants consenting to the study complete the 12-week assessment * Safety: no increase in the rate of bony events above those estimated to occur in the target population * Adherence: average completion of ≥ 75% of the exercise prescription amongst participants We will aim to recruit 25 participants from clinics at the local cancer hospital, the local disease-group support society, and from the currently accruing Alberta Cancer Exercise program. Subjects will be screened for eligibility and if they meet all eligibility criteria, an information letter of the study will be provided, and they will be asked to contact the investigators if interested in taking part in the study. All participants will be required to provide written informed consent as per the Health Research Ethics Board of Alberta: Cancer Committee (HREBA). Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises. Analyses: Demographic and medical information will be presented using median and range and percentage for interval and nominal data, respectively. Descriptive statistics (mean ± SD and frequencies) will be used to report safety and feasibility measures. Adherence will be tracked as the percentage of total training load prescribed that was actually completed. Wilcoxon Signed Rank Tests will be used to compare and pre- and post-intervention fitness assessment and quality of life scores. All analyses will be conducted using Stata/MP (version 13.0, StataCorp LLC, College Station, TX), with alpha set to 0.05.

Interventions

BEHAVIORALExercise

Participants will participate in a 12-week virtually supported home-based aerobic and resistance exercise program, twice weekly using the Heal-Me application. Sessions will be completed as virtual live classes or supported follow-along independent home workouts. Sessions will progress in duration and difficulty over the course of the program, aiming to have participants meet the 2019 Exercise Guidelines for Cancer Survivors by the end of the program. Each session will include aerobic exercise (i.e. walking, cycling, or cardio circuit), and a full-body resistance training routine using free weights, body weight exercises, and/or bands, followed by balance and stretching exercises.

Sponsors

University of Alberta
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Single group before and after

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. 18 years of age and older 2. Diagnosis of multiple myeloma 3. In one of the following three treatment categories: * Transplant ineligible patients, currently in first line treatment * Transplant eligible patients, sufficiently recovered from transplantation (\>3 months following transplantation) * Patients with relapsed/recurrent myeloma with either 1-3 prior lines of treatment or 4+ prior lines 4. Able to provide informed written consent in English 5. Approved for physical activity participation by their oncologist and cleared for physical activity by the Certified Exercise Physiologist on the PAR-Q+

Exclusion criteria

1. Unstable cardiac/metabolic condition that would be deemed unsafe to exercise 2. Severe anemia 3. Spinal instability requiring surgical intervention 4. AL amyloidosis, solitary plasmacytoma, or Waldenstrom macroglobulinemia 5. Too frail to participate in home exercise, as determine by baseline physical assessment (i.e., unable to complete a single sit-to-stand or balance on one foot for ≥ 3 seconds). 6. Inability to provide consent 7. Inability to commit to, and/or comply with the intervention due to personal reasons (e.g. vacation planned during the intervention period)

Design outcomes

Primary

MeasureTime frameDescription
Feasibility (Adherence)12 weeksThe percentage of total exercise dose prescribed that was actually completed (%)

Secondary

MeasureTime frameDescription
Feasibility (Recruitment rate)7 monthsThe number of participants recruited per month over the recruitment period and the proportion of patients who participate in the study, out of the total number of eligible patients
Feasibility (Completion rate)12 weeksThe number of participants who completed the program and follow-up assessment out of the number of participants who consented to the study
Feasibility (Safety)12 weeksThe number of adverse events reported by the participants during program participation, including the 12-week program and fitness assessments

Other

MeasureTime frameDescription
BalanceChange from baseline to 12 weeksChange in one legged stance test (seconds
Balance ConfidenceChange from baseline to 12 weeksActivities-specific Balance Confidence (ABC) scale (score)
Upper Extremity FunctionChange from baseline to 12 weeksChange in Upper Extremity Functional Index (score)
Lower Extremity FunctionChange from baseline to 12 weeksChange in Lower Extremity Functional Scale (score)
Cancer-Specific Quality of LifeChange from baseline to 12 weeksChange in Functional Assessment of Cancer Therapy General, Multiple Myeloma, and Bone Pain Scales (score)
FatigueChange from baseline to 12 weeksChange in FACIT-Fatigue Subscale (score)
Home-based Stepping TestChange from baseline to 12 weeksChange in 2-minute stepping test (number of steps)
Upper Extremity Grip Strength (optional)Change from baseline to 12 weeksHand-grip dynamometry (kg)
Upper extremity strength (optional)Change from baseline to 12 weeksOne repetition maximum bench press (kg)
Lower extremity strength (optional)Change from baseline to 12 weeksOne repetition maximum leg press (kg)
Core Endurance (optional)Change from baseline to 12 weeksPlank hold (seconds)
Fall risk (optional)Change from baseline to 12 weeksThree-metre backwards walk test (seconds)
Six-minute walk test (optional)Change from baseline to 12 weeksSix-minute walk test distance (metres)
Shoulder flexibilityChange from baseline to 12 weeksChange in active shoulder flexion range of motion (degrees)
Lower Body FlexibilityChange from baseline to 12 weeksChange in sit-and-reach test (cm)
Leg StrengthChange from baseline to 12 weeksChange in 30-second sit-to-stand (number of repetitions)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026